Patents by Inventor Nathan Genung

Nathan Genung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230117898
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y, Y2, R3 and R4 are defined herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: April 20, 2023
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20230060003
    Abstract: Described herein are compounds represented by formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R2, R3, R4, R5, R6, Y1, Y2, D, E, G1, G2, n and p are as defined herein.
    Type: Application
    Filed: October 28, 2020
    Publication date: February 23, 2023
    Inventors: Nathan Genung, Kevin M. Guckian, Lei Zhang, Zhili Xin, Jeffrey Vessels, Ryan Gianatassio
  • Patent number: 11459324
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 4, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Patent number: 11427561
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: August 30, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Timothy Chan, Kevin M. Guckian, Tracy Jenkins, Jermaine Thomas, Jeffrey Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph P. Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield, Nathan Genung
  • Publication number: 20220259197
    Abstract: Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical comositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, and Z are as defined herein.
    Type: Application
    Filed: March 6, 2020
    Publication date: August 18, 2022
    Applicant: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20220106305
    Abstract: Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, n and p are as defined herein.
    Type: Application
    Filed: February 3, 2020
    Publication date: April 7, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20220041586
    Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 10, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20220017506
    Abstract: Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, m, n, and p are as defined herein.
    Type: Application
    Filed: December 4, 2019
    Publication date: January 20, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20210188809
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.
    Type: Application
    Filed: January 18, 2017
    Publication date: June 24, 2021
    Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffrey Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph P. Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield, Nathan Genung
  • Publication number: 20210040080
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 11, 2021
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin